Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Public offering nets $24.6mm for Verastem

Executive Summary

Oncology drug developer Verastem Inc. netted $24.6mm through a public sale of 8.4mm common shares at $2.97. Funds will support launch and commercialization costs of the company's lead blood cancer candidate duvelisib, pending regulatory approval, and will also be put towards continued development of additional pipeline projects.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register